A cohort study on correlation between the progression of metabolic diseases and dampness constitution of Chinese Medicine

注册号:

Registration number:

ITMCTR2100005307

最近更新日期:

Date of Last Refreshed on:

2021-09-14

注册时间:

Date of Registration:

2021-09-14

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

中医湿性体质与相关代谢性疾病关系的队列研究

Public title:

A cohort study on correlation between the progression of metabolic diseases and dampness constitution of Chinese Medicine

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于体质分类的湿性体质与相关疾病关系队列研究

Scientific title:

A cohort study on relation with metabolic diseases and body constitution of Chinese medicine

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2100051123 ; ChiMCTR2100005307

申请注册联系人:

禤美玲

研究负责人:

温泽淮

Applicant:

Meiling Xuan

Study leader:

Zehuai Wen

申请注册联系人电话:

Applicant telephone:

+86 020-81887233-35838

研究负责人电话:

Study leader's telephone:

+86 020-81887233-35838

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

meilingxuan@gzucm.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

wenzh@gzucm.edu.cn

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

广东省广州市越秀区大德路111号

研究负责人通讯地址:

广东省广州市越秀区大德路111号

Applicant address:

111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China

Study leader's address:

111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

广东省中医院

Applicant's institution:

Guangdong Provincial Hospital of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

BF2021-017-01

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

广东省中医院伦理委员会

Name of the ethic committee:

Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2021/3/3 0:00:00

伦理委员会联系人:

李晓彦

Contact Name of the ethic committee:

Xiaoyan Li

伦理委员会联系地址:

广东省广州市越秀区海珠中路88号

Contact Address of the ethic committee:

No.88 Road, Yuexiu District, Guangzhou, Guangdong.

伦理委员会联系人电话:

Contact phone of the ethic committee:

020-81887233转35943

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广东省中医院

Primary sponsor:

Guangdong Provincial Hospital of Chinese Medicine

研究实施负责(组长)单位地址:

广东省广州市越秀区大德路111号

Primary sponsor's address:

111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院

具体地址:

广东省广州市越秀区大德路111号

Institution
hospital:

Guangdong Provincial Hospital of Chinese Medicine

Address:

111 Dade Road, Yuexiu District, Guangzhou, Guangdong, China

经费或物资来源:

省部共建中医湿证国家重点实验室专项

Source(s) of funding:

The State Key Laboratory of Dampness Syndrome of Chinese Medicine, China.

研究疾病:

代谢性疾病、中医湿性体质

研究疾病代码:

Target disease:

metabolic disease and dampness constitution of CM

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

队列研究

Cohort study

研究所处阶段:

Study phase:

其它

Others

研究目的:

建立中医湿证健康或亚健康人群登记队列,通过规范的队列信息采集和随访,以及生物标本的收集,明确此类人群的证素特点和证侯演变规律,揭示病证结合模式下湿证与代谢性疾病发生和发展的相关性。

Objectives of Study:

The study aims to establish a registration cohort of healthy or sub-healthy people with dampness constitution in Chinese medicine (CM) by collecting clinical data and biological sample. The study also wants to clarify the CM syndrome characteristics and the law of development of CM syndrome, and to reveal the correlation between the dampness constitution and the occurrence and development of metabolic diseases.

药物成份或治疗方案详述:

无。

Description for medicine or protocol of treatment in detail:

Not applicable.

纳入标准:

① 年龄18周岁及以上; ② 同意进行中医体质辨识; ③ 签署知情同意书。

Inclusion criteria

1. Age 18 and above. 2. Consented to take the CM constitution identification. 3. Sign informed consent.

排除标准:

① 确诊代谢性疾病,包括高脂血症、糖尿病、高尿酸血症、代谢综合征; ② 患有循环系统、呼吸系统、消化系统、内分泌系统、泌尿系统和造血系统等严重原发性疾病、肿瘤及精神病; ② 无法长期随访者。

Exclusion criteria:

1. Diagnosed metabolic diseases, including hyperlipidemia, diabetes, hyperuricemia, and metabolic syndrome. 2. Suffering from serious primary diseases, tumors and psychosis such as circulatory system, respiratory system, digestive system, endocrine system, urinary system and hematopoietic system. 3. Unable to participate in long-term follow-up.

研究实施时间:

Study execute time:

From 2021-01-01

To      2025-12-31

征募观察对象时间:

Recruiting time:

From 2021-09-01

To      2025-12-31

干预措施:

Interventions:

组别:

不适用

样本量:

17000

Group:

Not applicable.

Sample size:

干预措施:

不适用

干预措施代码:

Intervention:

Not applicable.

Intervention code:

样本总量 Total sample size : 2000

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

广东

市(区县):

佛山

Country:

China

Province:

Guangdong

City:

Foshan

单位(医院):

村落

单位级别:

N/A

Institution/hospital:

village

Level of the institution:

N/A

国家:

中国

省(直辖市):

广东

市(区县):

Country:

China

Province:

Guangdong

City:

单位(医院):

广州市干部疗养院

单位级别:

N/A

Institution/hospital:

Level of the institution:

N/A

国家:

中国

省(直辖市):

广东

市(区县):

广州

Country:

China

Province:

Guangdong

City:

Guangzhou

单位(医院):

广东省中医院

单位级别:

三级甲等

Institution/hospital:

Guangdong Provincial Hospital of Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

确诊高脂血症

指标类型:

主要指标

Outcome:

Diagnosis of hyperlipidemia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

确诊2型糖尿病

指标类型:

主要指标

Outcome:

Diagnosis of type 2 diabetes

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

确诊高尿酸血症

指标类型:

主要指标

Outcome:

Diagnosis of hyperuricemia

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

代谢性疾病诊断

指标类型:

主要指标

Outcome:

incidence of metabolic diseases

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

尿液

组织:

Sample Name:

urine

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用。

Randomization Procedure (please state who generates the random number sequence and by what method):

Not applicable.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不适用

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not applicable.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集使用病例记录表与电子采集管理系统相结合的方法。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case record form and electronic data capture will be used for data collection and data management.

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above